NCT04816682View on ClinicalTrials.gov

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

December 30, 2021

Conditions
Covid19Liver Diseases
Interventions
DRUG

Silymarin

Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D

Trial Locations (2)

82101

University Hospital Bratislava, Bratislava

97401

F.D.Roosevelt Teaching Hospital, Banská Bystrica

All Listed Sponsors
lead

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

OTHER

NCT04816682 - Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes | Biotech Hunter | Biotech Hunter